These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

965 related items for PubMed ID: 19381769

  • 1. Use of apomorphine in Parkinson's disease.
    Stocchi F.
    Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
    [Abstract] [Full Text] [Related]

  • 2. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW, Obeso JA, Stocchi F.
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [Abstract] [Full Text] [Related]

  • 3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 4. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T.
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [Abstract] [Full Text] [Related]

  • 5. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R, Barbier P, Corsini GU.
    J Neural Transm Suppl; 1995 Sep; 45():133-6. PubMed ID: 8748618
    [Abstract] [Full Text] [Related]

  • 6. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
    Baas H, Harder S, Bürklin F, Demisch L, Fischer PA.
    Clin Neuropharmacol; 1998 Sep; 21(2):86-92. PubMed ID: 9579293
    [Abstract] [Full Text] [Related]

  • 7. Myths and realities of continuous dopaminergic stimulation.
    Pirtošek Z.
    Psychiatr Danub; 2011 Mar; 23(1):80-3. PubMed ID: 21448103
    [Abstract] [Full Text] [Related]

  • 8. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
    Mov Disord; 2002 Mar; 17 Suppl 4():S83-9. PubMed ID: 12211146
    [No Abstract] [Full Text] [Related]

  • 9. Continuous dopaminergic stimulation in Parkinson's disease.
    Obeso JA, Luquin MR, Vaamonde J, Grandas F, Martinez Lage JM.
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
    [Abstract] [Full Text] [Related]

  • 10. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM, Houeto JL.
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [Abstract] [Full Text] [Related]

  • 11. An approach to the continuous dopaminergic stimulation in Parkinson's disease.
    Schwartz M, Sabetay S.
    Isr Med Assoc J; 2012 Mar; 14(3):175-9. PubMed ID: 22675859
    [Abstract] [Full Text] [Related]

  • 12. [Continuous subcutaneous infusion of apomorphine in Parkinson's disease: retrospective analysis of a series of 81 patients].
    Rambour M, Moreau C, Salleron J, Devos D, Kreisler A, Mutez E, Simonin C, Annic A, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2014 Mar; 170(3):205-15. PubMed ID: 24594365
    [Abstract] [Full Text] [Related]

  • 13. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M, Reichmann H, Riederer P.
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract] [Full Text] [Related]

  • 14. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease.
    Di Rosa AE, Epifanio A, Antonini A, Stocchi F, Martino G, Di Blasi L, Tetto A, Basile G, Imbesi D, La Spina P, Di Raimondo G, Morgante L.
    Neurol Sci; 2003 Oct; 24(3):174-5. PubMed ID: 14598073
    [Abstract] [Full Text] [Related]

  • 15. Use of apomorphine in clinical practice.
    MacMahon DG.
    Adv Neurol; 1999 Oct; 80():529-33. PubMed ID: 10410767
    [No Abstract] [Full Text] [Related]

  • 16. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W.
    Neurology; 2009 Feb 17; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [Abstract] [Full Text] [Related]

  • 17. Apomorphine therapy in Parkinson's disease: a review.
    Haq IU, Lewitt PA, Fernandez HH.
    Expert Opin Pharmacother; 2007 Nov 17; 8(16):2799-809. PubMed ID: 17956200
    [Abstract] [Full Text] [Related]

  • 18. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
    Grandas FJ, Sesar-Ignacio Á.
    Rev Neurol; 2012 Nov 17; 55 Suppl 1():S21-4. PubMed ID: 23169229
    [Abstract] [Full Text] [Related]

  • 19. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
    Pot C, Oppliger R, Castillo V, Coeytaux A, Hauser C, Burkhard PR.
    Neurology; 2005 Jan 25; 64(2):392-3. PubMed ID: 15668455
    [No Abstract] [Full Text] [Related]

  • 20. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
    Vaamonde J, Luquin MR, Obeso JA.
    Mov Disord; 1990 Jan 25; 5(3):260-2. PubMed ID: 2388647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.